A NON-INTERVENTIONAL OBSERVATIONAL RETROSPECTIVE STUDY OF SECOND-LINE TREATMENT WITH THE COMBINATION DARATUMUMAB - BORTEZOMIB - DEXAMETHASONE (DARAVD) IN MULTIPLE MYELOMA PATIENTS REFRACTORY TO LENALIDOMIDE

被引：0
|
作者：
Rizzello, I. [1 ]
Zamagni, E. [1 ]
Solli, V. [1 ]
Poletti, A. [1 ]
Tacchetti, P. [1 ]
Pantani, L. [1 ]
Mancuso, K. [1 ]
Rocchi, S. [1 ]
De Cicco, G. [1 ]
Fusco, A. [1 ]
Ursi, M. [1 ]
Barbato, S. [1 ]
Terragna, C. [1 ]
Martello, M. [1 ]
Testoni, N. [1 ]
Marzocchi, G. [1 ]
Cavo, M. [1 ]
机构：
[1] Univ Bologna, Dipartimentodi Med Specialist Diagnost & Sperimen, Ist Ematol Seragnoli, IRCCS Azienda Osped, Bologna, Italy
来源：
HAEMATOLOGICA | 2021年 / 106卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
D135
引用
收藏
页码：167 / 168
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile
    Aceituno, Susana
    Gozalbo, Irmina
    Appierto, Marilena
    Lizan, Luis
    [J]. MEDWAVE, 2018, 18 (03):
  • [2] EFFICACY BY CYTOGENETIC RISK STATUS FOR DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE OR BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    San-Miguel, J.
    Weisel, K.
    Cook, G.
    Leiba, M.
    Suzuki, K.
    Kumar, S.
    Cavo, M.
    Avet-Loiseau, H.
    Quach, H.
    Hungria, V.
    Lentzsch, S.
    Hajek, R.
    Sonneveld, P.
    Wu, K.
    Qin, X.
    Chiu, C.
    Soong, D.
    Qi, M.
    Schecter, J.
    Dimopoulos, M. A.
    [J]. HAEMATOLOGICA, 2017, 102 : 1 - 2
  • [3] Revlimid-NIS: Non-interventional study on therapy of relapsed/refractory multiple myeloma with a combination of lenalidomide plus dexamethasone
    Knauf, W.
    Aldaoud, A.
    Maintz, C.
    Groschek, M.
    Teichmann, B.
    Harde, J.
    Trarbach, T.
    [J]. Oncology Research and Treatment, 2015, 38 : 238 - 238
  • [4] Therapy of relapsed/refractory multiple myeloma with a combination of Lenalidomide plus Dexamethasone: First interim analysis of the non-interventional study "Revlimid"
    Knauf, W.
    Aldaoud, A.
    Groschek, M.
    Teichmann, B.
    Harde, J.
    Hasskarl, J.
    [J]. ONKOLOGIE, 2013, 36 : 154 - 155
  • [5] Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients—a single-center retrospective study
    Bernard Regidor
    Marissa-Skye Goldwater
    Jessica Wang
    Sean Bujarski
    Regina Swift
    Benjamin Eades
    Marsiye Emamy-Sadr
    Shahrooz Eshagian
    Gary Schwartz
    Tanya M. Spektor
    James R. Berenson
    [J]. Annals of Hematology, 2021, 100 : 2061 - 2070
  • [6] Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
    Sonneveld, Pieter
    Zweegman, Sonja
    Cavo, Michele
    Nasserinejad, Kazem
    Broijl, Annemiek
    Troia, Rosella
    Pour, Ludek
    Croockewit, Sandra
    Corradini, Paolo
    Patriarca, Francesca
    Wu, Kalung
    Droogendijk, Jolanda
    Bos, Gerard
    Hajek, Roman
    Teresa Petrucci, Maria
    Ypma, Paula
    Zojer, Nicholas
    Minnema, Monique C.
    Boccadoro, Mario
    [J]. HEMASPHERE, 2022, 6 (10): : E786
  • [7] THALIDOMIDE OR BORTEZOMIB IN COMBINATION WITH DEXAMETHASONE AS SECOND-LINE THERAPY FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA: A COMPARISON OF EFFICACY AND TOXICITY
    Varettoni, M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 385 - 385
  • [8] Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
    Shinsuke Iida
    Tatsuo Ichinohe
    Atsushi Shinagawa
    Kenshi Suzuki
    Naoki Takezako
    Masayuki Aoki
    [J]. International Journal of Hematology, 2018, 107 : 460 - 467
  • [9] Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
    Iida, Shinsuke
    Ichinohe, Tatsuo
    Shinagawa, Atsushi
    Suzuki, Kenshi
    Takezako, Naoki
    Aoki, Masayuki
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (04) : 460 - 467
  • [10] Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study
    Regidor, Bernard
    Goldwater, Marissa-Skye
    Wang, Jessica
    Bujarski, Sean
    Swift, Regina
    Eades, Benjamin
    Emamy-Sadr, Marsiye
    Eshagian, Shahrooz
    Schwartz, Gary
    Spektor, Tanya M.
    Berenson, James R.
    [J]. ANNALS OF HEMATOLOGY, 2021, 100 (08) : 2061 - 2070
12345